详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Pharmacology, School of Pharmacy, Laboratory of Molecular Pharmacology, Southwest Medical University, Luzhou, Sichuan, 646000, China. [2]Scientific Research and Experimental Training Center, Sichuan College of Traditional Chinese Medicine, Mianyang, China. [3]School of Nursing, Chongqing College of Humanities, Science & Technology, Chongqing, 401520, China. [4]Department of Pharmacy, Mianyang Hospital of TCM, Sichuan Mianyang, 621000, China. [5]South Sichuan Institute of Translational Medicine, Luzhou, 646000, China.

出处：

DOI：

关键词： RNA modification Cancer drug resistance Small molecule modulators m6A m5C m7G

摘要：

As the role of RNA modification in gene expression regulation and human diseases, the "epitranscriptome" has been shown to be an important player in regulating many physiological and pathological processes. Meanwhile, the phenomenon of cancer drug resistance is becoming more and more frequent, especially in the case of cancer chemotherapy resistance. In recent years, research on relationship between post-transcriptional modification and cancer including drug resistance has become a hot topic, especially the methylation of the sixth nitrogen site of RNA adenosine-m6A (N6-methyladenosine). m6A modification is the most common post-transcriptional modification of eukaryotic mRNA, accounting for 80% of RNA methylation modifications. At the same time, several other modifications of RNA, such as N1-methyladenosine (m1A), 5-methylcytosine (m5C), 3-methylcytosine (m3C), pseudouridine (Ψ) and N7-methylguanosine (m7G) have also been demonstrated to be involved in cancer and drug resistance. This review mainly discusses the research progress of RNA modifications in the field of cancer and drug resistance and targeting of m6A regulators by small molecule modulators, providing reference for future study and development of combination therapy to reverse cancer drug resistance.© 2024. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 2 区生物学

小类 | 2 区细胞生物学

第一作者：

第一作者机构： [1]Department of Pharmacology, School of Pharmacy, Laboratory of Molecular Pharmacology, Southwest Medical University, Luzhou, Sichuan, 646000, China. [2]Scientific Research and Experimental Training Center, Sichuan College of Traditional Chinese Medicine, Mianyang, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Pharmacology, School of Pharmacy, Laboratory of Molecular Pharmacology, Southwest Medical University, Luzhou, Sichuan, 646000, China. [5]South Sichuan Institute of Translational Medicine, Luzhou, 646000, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. [2]m6A/ m1A /m5C/m7G-related methylation modification patterns and immune characterization in prostate cancer [3]RNA m6A modification in prostate cancer: A new weapon for its diagnosis and therapy [4]Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics [5]Autophagy modulation in cancer therapy: Challenges coexist with opportunities [6]The role of N6-methyladenosine (m6A) in kidney diseases [7]Nanomedicine Combats Drug Resistance in Lung Cancer [8]FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-6-Methyladenosine RNA Demethylase [9]Protein degradation: expanding the toolbox to restrain cancer drug resistance [10]Editorial: Non-genetic adaptive drug resistance in cancer